ArticleThe Journal of experimental medicine2004
B lineage-specific regulation of V(D)J recombinase activity is established in common lymphoid progenitors.
Article in The Journal of experimental medicine, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 121 citations in OpenAlex.
- RAG recombinase expression discriminates the development of natural killer cells.Frontiers in immunology · 2025Article
- Lineage- and stage-specific activity of antigen receptor gene enhancers during lymphocyte development.Frontiers in epigenetics and epigenomics · 2024Review
- DRAG in situ barcoding reveals an increased number of HSPCs contributing to myelopoiesis with age.Nature communications · 2023Article
- Single-cell landscape dissecting the transcription and heterogeneity of innate lymphoid cells in ischemic heart.Frontiers in immunology · 2023Article
- Genotoxic stress signalling as a driver of macrophage diversity.Cell stress · 2022Review
- Radiofrequency EMF irradiation effects on pre-B lymphocytes undergoing somatic recombination.Scientific reports · 2021Article
- Systematic Analysis of an Invasion-Related 3-Gene Signature and Its Validation as a Prognostic Model for Pancreatic Cancer.Frontiers in oncology · 2021Article
- CD56 as a marker of an ILC1-like population with NK cell properties that is functionally impaired in AML.Blood advances · 2019Article
- At the intersection of DNA damage and immune responses.Nature reviews. Immunology · 2019Review
- RAG gene defects at the verge of immunodeficiency and immune dysregulation.Immunological reviews · 2019Review
- V(D)J Recombination Exploits DNA Damage Responses to Promote Immunity.Trends in genetics : TIG · 2017Review
- Natural Killer Cells from Patients with Recombinase-Activating Gene and Non-Homologous End Joining Gene Defects Comprise a Higher Frequency of CD56Frontiers in immunology · 2017Article
- Human RAG mutations: biochemistry and clinical implications.Nature reviews. Immunology · 2016Review
- Novel molecular mechanism for generating NK-cell fitness and memory.European journal of immunology · 2015Review
- The RAG recombinase dictates functional heterogeneity and cellular fitness in natural killer cells.Cell · 2014Article
- Cell-intrinsic in vivo requirement for the E47-p21 pathway in long-term hematopoietic stem cells.Journal of immunology (Baltimore, Md. : 1950) · 2014Article
- Enhancing T lineage production in aged mice: a novel function of Foxn1 in the bone marrow niche.Journal of immunology (Baltimore, Md. : 1950) · 2013Article
- A Novel Quantitative Fluorescent Reporter Assay for RAG Targets and RAG Activity.Frontiers in immunology · 2013Article
- Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
Abstract
Expression of V(D)J recombinase activity in developing lymphocytes is absolutely required for initiation of V(D)J recombination at antigen receptor loci. However, little is known about when during hematopoietic development the V(D)J recombinase is first active, nor is it known what elements activate the recombinase in multipotent hematopoietic progenitors. Using mice that express a fluorescent transgenic V(D)J recombination reporter, we show that the V(D)J recombinase is active as early as common lymphoid progenitors (CLPs) but not in the upstream progenitors that retain myeloid lineage potential. Evidence of this recombinase activity is detectable in all four progeny lineages (B, T, and NK, and DC), and rag2 levels are the highest in progenitor subsets immediately downstream of the CLP. By single cell PCR, we demonstrate that V(D)J rearrangements are detectable at IgH loci in approximately 5% of splenic natural killer cells. Finally, we show that recombinase activity in CLPs is largely controlled by the Erag enhancer. As activity of the Erag enhancer is restricted to the B cell lineage, this provides the first molecular evidence for establishment of a lineage-specific transcription program in multipotent progenitors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.